Investigating the Effects of Camellia petelotii Chi Extract on Nonalcoholic Fatty Liver Disease Based on TLR-4/NF-κB Signaling Pathway

To examine the effects and mechanisms of Camellia petelotii Chi extract on the rat model of non-alcoholic fatty liver disease (NAFLD), a set of ten SD rats was randomly chosen as the blank group, while the remaining 50 rats were given a high-sugar, high-fat emulsion to develop the model of non-alcoholic fatty liver disease. After 14 days, the rats were separated into different groups based on their serum total cholesterol (TC) levels. These groups included the model group, the simvastatin group (8 mg/kg), and the Camellia petelotii Chi high, medium, and low dose groups (260, 130, 65 mg/kg). The medication was administered continuously for 6 weeks. Before the last administration, an oral glucose tolerance test (OGTT) was performed, and the area under the blood glucose curve (AUC) was calculated. Both serum and liver tissues were collected to examine the concentrations of total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), and free fatty acid (FFA). I